2023
Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer
Li G, Hu J, Cho C, Cui J, Li A, Ren P, Zhou J, Wei W, Zhang T, Liu X, Liu W. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer. Cellular Signalling 2023, 109: 110729. PMID: 37257766, DOI: 10.1016/j.cellsig.2023.110729.Peer-Reviewed Original ResearchConceptsT cell tumor infiltrationTriple-negative breast cancerCD8+ T cell tumor infiltrationBreast cancerTumor infiltrationLack of target receptorsAnti-PD-1 antibodyAggressive subtype of breast cancerModels of triple-negative breast cancerSubtypes of breast cancerPD-L1 expressionEstrogen-positive breast cancerMTOR inhibitor everolimusPositive breast cancerProgression of triple-negative breast cancerReduced tumor growthAvailable treatment optionsCombination treatment strategiesPromote cancer cell survivalTreatment of estrogen-positive breast cancerAttenuate tumor progressionNonspecific cytotoxic agentsCancer cell survivalVascular endothelial cellsPotential therapeutic strategy
2022
Estimation of neutral mutation rates and quantification of somatic variant selection using canceffectsizeR
Mandell J, Cannataro V, Townsend J. Estimation of neutral mutation rates and quantification of somatic variant selection using canceffectsizeR. Cancer Research 2022, 83: 500-505. PMID: 36469362, PMCID: PMC9929515, DOI: 10.1158/0008-5472.can-22-1508.Peer-Reviewed Original ResearchConceptsMutation rateEpistatic effectsSite-specific mutation ratesNeutral mutation rateNucleotide mutation ratePan-cancer datasetCancer cell survivalFunctional impact scoresCustom genomesPairwise epistasisSet of variantsHuman genomeR packageTranscriptomic dataSomatic variant dataModel of selectionSingle nucleotideCancer effectsCell survivalNucleotide mutationsCancer biologyVariant dataMutational signature analysisMutationsSomatic mutations
2021
Network propagation-based prioritization of long tail genes in 17 cancer types
Mohsen H, Gunasekharan V, Qing T, Seay M, Surovtseva Y, Negahban S, Szallasi Z, Pusztai L, Gerstein MB. Network propagation-based prioritization of long tail genes in 17 cancer types. Genome Biology 2021, 22: 287. PMID: 34620211, PMCID: PMC8496153, DOI: 10.1186/s13059-021-02504-x.Peer-Reviewed Original ResearchConceptsCancer-relevant genesTail genesMobility genesNetwork propagation approachGenome-wide RNAiNetwork propagation methodCancer developmentPotential functional impactCancer cell survivalNew genesUnreported genesFunctional screeningCancer typesFunctional importanceCancer genesNovel potential therapeutic targetDriver genesCell survivalGenesMutational distributionsBiological interactionsPotential therapeutic targetFunctional impactGenomic alterationsInfrequent mutationsRenalase: A Multi-Functional Signaling Molecule with Roles in Gastrointestinal Disease
Pointer TC, Gorelick FS, Desir GV. Renalase: A Multi-Functional Signaling Molecule with Roles in Gastrointestinal Disease. Cells 2021, 10: 2006. PMID: 34440775, PMCID: PMC8391834, DOI: 10.3390/cells10082006.Peer-Reviewed Original ResearchConceptsProsurvival effectAcute cerulein pancreatitisRole of renalaseAnti-inflammatory effectsDisease modelsAcute organ injuryRelevant clinical settingsShortens life expectancyPreclinical disease modelsCell survivalHuman cancer tissuesCancer cell survivalOrgan injuryAcute injuryPancreatic cancerIntestinal diseaseGastrointestinal diseasesRodent modelsCerulein pancreatitisSelect cancersCancer tissuesRenalaseClinical settingTherapeutic agentsExport transportersNoncanonical open reading frames encode functional proteins essential for cancer cell survival
Prensner J, Enache O, Luria V, Krug K, Clauser K, Dempster J, Karger A, Wang L, Stumbraite K, Wang V, Botta G, Lyons N, Goodale A, Kalani Z, Fritchman B, Brown A, Alan D, Green T, Yang X, Jaffe J, Roth J, Piccioni F, Kirschner M, Ji Z, Root D, Golub T. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nature Biotechnology 2021, 39: 697-704. PMID: 33510483, PMCID: PMC8195866, DOI: 10.1038/s41587-020-00806-2.Peer-Reviewed Original ResearchConceptsCancer cell linesOpen reading framePotential therapeutic targetCell linesGrowth inhibitory effectsCancer cell survivalInduced gene expression changesBreast cancerTherapeutic targetHuman cancer cell linesReading frameProtein expressionActive proteinProtein 1Gene expression changesCell survivalBiological effectsExpression changesViability defectsHuman genomeGenomic analysisCodon mutagenesisEctopic expressionFunctional proteinsKnockout
2020
TBIO-26. NON-CANONICAL OPEN READING FRAMES ENCODE FUNCTIONAL PROTEINS ESSENTIAL FOR CANCER CELL SURVIVAL
Prensner J, Enache O, Luria V, Krug K, Clauser K, Dempster J, Karger A, Wang L, Stumbraite K, Wang V, Botta G, Lyons N, Goodale A, Kalani Z, Fritchman B, Brown A, Alan D, Green T, Yang X, Jaffe J, Roth J, Piccioni F, Kirschner M, Ji Z, Root D, Golub T. TBIO-26. NON-CANONICAL OPEN READING FRAMES ENCODE FUNCTIONAL PROTEINS ESSENTIAL FOR CANCER CELL SURVIVAL. Neuro-Oncology 2020, 22: iii471-iii471. PMCID: PMC7715501, DOI: 10.1093/neuonc/noaa222.849.Peer-Reviewed Original ResearchOpen reading frameNon-canonical open reading framesProtein translationReading frameMultiple cancer typesPutative non-coding RNAProtein-coding genesSingle-cell RNA sequencingNon-canonical proteinsFunctional genomic screensCancer-implicated genesCancer cell linesCell-autonomous mannerNon-coding RNANon-coding RNAsGene expression changesPotential cancer therapeutic targetCell linesHEK293T cellsCancer cell survivalCancer therapeutic targetNon-gonadal tissuesCell cycle arrestRibosome profilingCancer cell types
2019
24R,25-Dihydroxyvitamin D3 regulates breast cancer cells in vitro and in vivo
Verma A, Cohen DJ, Schwartz N, Muktipaty C, Koblinski JE, Boyan BD, Schwartz Z. 24R,25-Dihydroxyvitamin D3 regulates breast cancer cells in vitro and in vivo. Biochimica Et Biophysica Acta (BBA) - General Subjects 2019, 1863: 1498-1512. PMID: 31125679, DOI: 10.1016/j.bbagen.2019.05.013.Peer-Reviewed Original ResearchConceptsEstrogen receptorMCF7 tumor growthBreast cancer patientsBreast cancer cell survivalBreast cancer xenograftsNarrow therapeutic windowMammary fat padDose-dependent increasePre-clinical studiesNull female miceMarker of invasionAnti-proliferative effectsBreast cancer cellsCell survivalCancer cell survivalTumor burdenAnti-tumorigenic propertiesVitamin DCancer patientsCancer xenograftsFemale miceHigh serumBreast cancerDihydroxyvitamin D3Therapeutic window
2016
Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes
Sethi T, Kovach A, Rubinstein S, Lee L, Wang Y, Morgan D, Greer J, Vnencak-Jones C, Reddy N. Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes. Blood 2016, 128: 929. DOI: 10.1182/blood.v128.22.929.929.Peer-Reviewed Original ResearchCentral nervous system lymphomaPD-1/PD-L1 expressionProgression-free survivalPD-L1 expressionToll-like receptorsPD-1/PD-L1Diffuse large B-cell lymphomaPD-1/ PDNervous system lymphomaPD-L1Overall survivalMYD88 mutationsPD-1System lymphomaStimulation of TLRsCancer cell survivalHigh-dose methotrexate-based therapySystemic diffuse large B-cell lymphomaCo-expressing PD-1Median progression-free survivalPrior solid organ transplantMyeloid differentiation primary response protein 88Adaptor proteinAdvisory CommitteeB-cell receptor pathway
2014
p53 protein aggregation promotes platinum resistance in ovarian cancer
Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2014, 34: 3605-3616. PMID: 25263447, DOI: 10.1038/onc.2014.296.Peer-Reviewed Original ResearchConceptsPro-apoptotic functionP53 aggregationProtein aggregationP53 aggregatesNormal transcriptional activationTwo-dimensional gel electrophoresisCancer cellsCancer cell survivalKey transcriptional factorGenetic mutationsHigh-grade serous ovarian carcinomaP53 inactivationP53 proteinStem cell propertiesCancer stem cell propertiesCellular homeostasisTranscriptional activationCancer stem cellsTranscriptional factorsTumor-initiating capacityP53 turnoverCell survivalHGSOC cellsStem cellsPotential therapeutic target
2011
Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
Anastasiou D, Poulogiannis G, Asara J, Boxer M, Jiang J, Shen M, Bellinger G, Sasaki A, Locasale J, Auld D, Thomas C, Vander Heiden M, Cantley L. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 2011, 334: 1278-1283. PMID: 22052977, PMCID: PMC3471535, DOI: 10.1126/science.1211485.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAmino Acid SubstitutionAnimalsAntioxidantsCell LineCell Line, TumorCell SurvivalCysteineDiamideEnzyme ActivatorsGlucoseGlutathioneHumansMiceMice, NudeMutant ProteinsNeoplasm TransplantationNeoplasms, ExperimentalOxidation-ReductionOxidative StressPentose Phosphate PathwayProtein SubunitsPyruvate KinaseReactive Oxygen SpeciesTransplantation, HeterologousConceptsPyruvate kinase M2Lung cancer cellsCancer cellsKinase M2Human lung cancer cellsReactive oxygen species contributesInhibition of PKM2Intracellular reactive oxygen species (ROS) concentrationCancer cell survivalCellular antioxidant responseGlycolytic enzyme pyruvate kinase M2Acute increaseXenograft modelReactive oxygen species concentrationMetabolic changesOxidative stressTumor formationGlucose fluxCell survivalIntracellular concentrationAntioxidant responseInhibitionCellsOxygen species concentrationROS
2006
Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment
Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment. Molecular Pharmacology 2006, 71: 259-275. PMID: 17050804, DOI: 10.1124/mol.106.031153.Peer-Reviewed Original ResearchConceptsMitogen-activated protein kinase kinaseProtein kinase kinaseKinase 1/2 signalingOverexpression of BclDominant-negative AktInhibition of phosphatidylinositolCoA reductase inhibitor lovastatinPan-caspase inhibitorExpression of BclCancer cell survivalHMG-CoA reductase inhibitor lovastatinApoptosis-inducing factor expressionProstate cancer cell survivalTreatment of cellsEpidermal growth factor receptorDominant-negative IkappaBInhibition of erbB1Kinase kinaseReductase inhibitor lovastatinGeranylgeranyl transferase inhibitorPARP1 functionGrowth factor receptorCytotoxic effectsCaspase-9Prostate cancer cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply